glp-1 release is released from the small intestine after meal ingestion and GLP-1 Genetics: How Genes Affect

Addressing Metabolic Dysfunction as an Independent Cancer Risk Factor Accumulating evidence positions metabolic dysfunction characterised by insulin resistance, hepatic steatosis, dyslipidaemia, and visceral adiposity as a more powerful and proximate predictor of cancer risk than elevated body weight alone

Critically, no natural supplement has been shown to replicate the clinical benefits of prescribed GLP-1 or GIP receptor agonists for diabetes management or weight loss

Dose management: Follow your physician prescribed semaglutide dose escalation schedule

A small retrospective analysis from 2024 suggested modest additional weight loss (13% more) when topiramate was added to semaglutide in patients who had plateaued, but the effect was inconsistent and accompanied by higher adverse-event rates in 40% of participants